Table 4.
Summary of variables and distributions considered in sensitivity analyses and Monte Carlo simulations
| Model parametersa | Low | High | Distributionb |
|---|---|---|---|
| Treatment | |||
| L-AMB, 50 mg i.v., cost/vial (€) | 97.95 | 163.26 | Gamma (64.1, 0.12) |
| Caspofungin | |||
| 70 mg i.v., cost/vial (€) | 428.11 | 713.51 | Gamma (66.24, 0.11) |
| 50 mg i.v., cost/vial (€) | 336.57 | 560.95 | Gamma (64, 0.14) |
| Voriconazole | |||
| 200 mg i.v., cost/vial (€) | 99.99 | 166.65 | Gamma (64, 0.16) |
| Oral tablet, cost (€) | 26.75 | 44.59 | Gamma (64.05, 0.9) |
| Fluconazole, 200 mg i.v., cost/vial (€) | 8.34 | 13.9 | Gamma (64, 5.75) |
| Days of administration as FLT | |||
| L-AMB | 7 | 14 | Gamma (64, 8.53), gamma (64, 5.12) |
| Caspofungin | 7 | 14 | Gamma (64, 5.82), gamma (64, 4.92) |
| Voriconazole | 14 | 28 | Gamma (64, 5.33) |
| Fluconazole | 7 | 14 | Gamma (64, 7.53) |
| Cost of hospitalization per day (€) | 300.97 | 501.25 | Gamma (64, 0.16) |
| Probabilities | |||
| EAT indication* | 0.508 | 0.715 | Beta (24.83, 15.74) |
| Persistent fever* | 0.325 | 0.648 | Beta (32.896, 34.791) |
| Premature discontinuation* | 0.063 | 0.315 | Beta (51.904, 222.72) |
| Breakthrough IFI in patients* | 0 | 0.079 | Beta (62.27, 2,244.1) |
| Death* | 0.15 | 0.445 | Beta (44.93, 105.84) |
| Persistent fever† | 0.345 | 0.686 | Beta (31, 29.23) |
| Successful response‡ | 0.177 | 0.50 | Beta (43.06, 83.97) |
| Unsuccessful response* | 0.566 | 0.858 | Beta (18.48, 7.51) |
a
L-AMB, liposomal amphotericin B; FLT, first-linetherapy. *, That is, in selected patients who received AT following the DDAT approach; †, that is, in patients who not receive AT following the DDATapproach; ‡, that is, in patients managed using the EAT approach.
b
Where two values are given, the first value indicates the DDAT approach recommended by the SAEI, and the second value is the EAT approach recommended by the IDSA.